InterpaceBiosciences_New Logo.png
Interpace Biosciences Announces Improved Coverage for ThyGeNEXT® and ThyraMIR®
May 03, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, May 03, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that eviCore Healthcare (“eviCore”), a wholly owned...
InterpaceBiosciences_New Logo.png
Interpace Biosciences to Explore Strategic Alternatives for Maximizing Shareholder Value
April 22, 2021 08:00 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 22, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today issued the following statement. Interpace continues to make...
InterpaceBiosciences_New Logo.png
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
April 19, 2021 07:05 ET | Interpace Biosciences, Inc.
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance...
LOGO.jpg
Interpace Biosciences Announces Full Year and Fourth Quarter 2019 Financial and Business Results and Preliminary Q1-2020 Results
April 22, 2020 16:05 ET | Interpace Biosciences, Inc.
Acquired Biopharma Business of Cancer Genetics in Second Half of 2019 Through Q1-2020 Raised $47 million from Two Top Private Equity FirmsProvides First Quarter 2020 Range of Revenues Expects to...
LOGO.jpg
Interpace Diagnostics Announces Contract with BCBS of Massachusetts
March 10, 2020 06:55 ET | Interpace Biosciences, Inc.
In-Network Access for More Than 3 Million Members Parsippany, NJ, March 10, 2020 (GLOBE NEWSWIRE) -- Interpace Diagnostics, a subsidiary of Interpace Biosciences (NASDAQ: IDXG) announced...
LOGO.jpg
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
January 13, 2020 06:55 ET | Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
LOGO.jpg
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
January 06, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
LOGO.jpg
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
Logo.png
Interpace Biosciences Launches New Corporate Website
December 02, 2019 06:55 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and...
Logo.png
Interpace to Present at the American College of Gastroenterology Conference
October 24, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Interpace hosts 2nd Annual Fellow Programs PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its...